Combined Pharmacophore and 3D-QSAR Study on A Series of Staphylococcus aureus Sortase A inhibitors

Chemical Biology and Drug Design

Volumn 80, Issue 2, 2012, Pages 300-314

  Uddin, Reaz ^a   Lodhi, Mazhar U ^a   Ul Haq, Zaheer ^a,b  

^a UNIVERSITY OF KARACHI   (Pakistan)

^b HEIDELBERG INSTITUTE FOR THEORETICAL STUDIES   (Germany)

Author keywords

Molecular diversity; Molecular modeling; Structure based drug design

Indexed keywords

ACYLTRANSFERASE INHIBITOR; ANTIINFECTIVE AGENT; PYRAZOLE DERIVATIVE; PYRAZOLETHIONE DERIVATIVE; PYRIDAZINONE DERIVATIVE; RHODANINE; SORTASE A INHIBITOR; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; BIOLOGICAL ACTIVITY; DATA BASE; DRUG IDENTIFICATION; GENETIC ALGORITHM; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR DOCKING; MOLECULAR MODEL; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STAPHYLOCOCCUS AUREUS; STATIC ELECTRICITY; STEREOSPECIFICITY; THREE DIMENSIONAL IMAGING;

AMINOACYLTRANSFERASES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CYSTEINE ENDOPEPTIDASES; DRUG DESIGN; ENZYME INHIBITORS; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

EID: 84863991812     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2012.01403.x     Document Type: Article

References (47)

1. Lowy F.D. (2003) Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest;111:1265-1273.
2. Diekema D.J., Pfaller M.A., Schmitz F.J., Smayevsky J., Bell J., Jones R.N., Beach M. (2001) Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis;32:114-132.
3. Mazmanian S.K., Liu G., Ton-That H., Schneewind O. (1999) Staphylococcus aureus sortase, an enzyme that anchors surface proteins to the cell wall. Science;285:760-763.
4. Ton-That H., Marraffini L.A., Schneewind O. (2004) Protein sorting to the cell wall envelope of Gram-positive bacteria. Biochim Biophys Acta;1694:269-278.
5. Paterson G.K., Mitchell T.J. (2004) The biology of Gram-positive sortase enzymes. Trends Microbiol;12:89-95.
6. Schneewind O., Model P., Fischetti V.A. (1992) Sorting of protein a to the staphylococcal cell wall. Cell;70:267-281.
7. Schneewind O., Mihaylova-Petkov D., Model P. (1993) Cell wall sorting signals in surface proteins of gram-positive bacteria. EMBO J;12:4803-4811.
8. Navarre W.W., Schneewind O. (1994) Proteolytic cleavage and cell wall anchoring at the LPXTG motif of surface proteins in Gram-positive bacteria. Mol Microbiol;14:115-121.
9. Ruzin A., Severin A., Ritacco F., Tabei K., Singh G., Bradford P.A., Siegel M.M., Projan S.J., Shlaes D.M. (2002) Further evidence that a cell wall precursor [C55-MurNAc-(peptide)-GlcNAc] serves as an acceptor in a sorting reaction. J Bacteriol;184:2141.
10. Perry A.M., Ton-That H., Mazmanian S.K., Schneewind O. (2002) Anchoring of surface proteins to the cell wall of Staphylococcus aureus. J Biol Chem;277:16241-16248.
11. Strominger J., Izaki K., Matsuhashi M., Tipper D. (1967) Peptidoglycan transpeptidase and d-alanine carboxypeptidase: penicillin-sensitive enzymatic reactions. Fed Proc;26:9-22.
12. Pallen M.J., Lam A.C., Antonio M., Dunbar K. (2001) An embarrassment of sortases-a richness of substrates? Trends Microbiol;9:97-101.
13. Janulczyk R., Rasmussen M. (2001) Improved pattern for genome-based screening identifies novel cell wall-attached proteins in gram-positive bacteria. Infect Immun;69:4019-4026.
14. Comfort D., Clubb R.T. (2004) A comparative genome analysis identifies distinct sorting pathways in gram-positive bacteria. Infect Immun;72:2710-2722.
15. Maresso A.W., Schneewind O. (2008) Sortase as a target of anti-infective therapy. Pharmacol Rev;60:128-141.
16. Suree N., Jung M.E., Clubb R.T. (2007) Recent advances towards new anti-infective agents that inhibit cell surface protein anchoring in Staphylococcus aureus and other Gram-positive pathogens. Mini-Rev Med Chem;7:991-1000.
17. Chang S., Sievert D.M., Hageman J.C., Boulton M.L., Tenover F.C., Downes F.P., Shah S., Rudrik J.T., Pupp G.R., Brown W.J. (2003) Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. New Engl J Med;348:1342-1347.
18. Waldvogel F.A. (1999) New resistance in Staphylococcus aureus. N Engl J Med;340:556-557.
19. Klevens R.M., Morrison M.A., Nadle J., Petit S., Gershman K., Ray S., Harrison L.H., Lynfield R., Dumyati G., Townes J.M. (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. J Am Med Assoc;298:1763.
20. Frank A.L., Marcinak J.F., Mangat P.D., Schreckenberger P.C. (1999) Increase in community-acquired methicillin-resistant Staphylococcus aureus in children. Clin Infect Dis;29:935-936.
21. Gorak E.J., Yamada S.M., Brown J.D. (1999) Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors. Clin Infect Dis;29:797-800.
22. Moran G.J., Mount J. (2003) Staphylococcus aureus resistant to vancomycin: United States, 2002. Commentary. J Ann Emerg Med;41:148-151.
23. Chambers H.F. (2001) The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis;7:178-182.
24. Talbot G.H., Bradley J., Edwards J.E. Jr, Gilbert D., Scheld M., Bartlett J.G. (2006) Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis;42:657-668.
25. Ul-Haq Z., Wadood A., Uddin R. (2009) CoMFA and CoMSIA 3D-QSAR analysis on hydroxamic acid derivatives as urease inhibitors. J Enzyme Inhib Med Chem;24:272-278.
26. Ul Haq Z., Uddin R., Wai L., Wadood A., Lajis N. (2011) Docking and 3D-QSAR modeling of cyclin-dependent kinase 5/p25 inhibitors. J Mol Model;17:1149-1161.
27. Ul Haq Z., Mahmood U., Jehangir B. (2009) Ligand based 3D QSAR studies of physostigmine analogues as acetylcholinesterase inhibitors. Chem Biol Drug Des;74:571-581.
28. Ul Haq Z., Mahmood U., Reza S., Uddin R., Aleem M. (2011) Ligand based 3D QSAR studies of diaryl acyl sulfonamide analogues as human umbilical vein endothelial cells inhibitors stimulated by VEGF. Chem Biol Drug Des;77:288-294.
29. Richmond N.J., Abrams C.A., Wolohan P.R.N., Abrahamian E., Willett P., Clark R.D. (2006) GALAHAD: 1. Pharmacophore identification by hypermolecular alignment of ligands in 3D. J Comput Aided Mol Des;20:567-587.
30. Richard D.C. III, David E.P., Jeffrey D.B. (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc;110:5959-5967.
31. Klebe G., Abraham U., Mietzner T. (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem;37:4130-4146.
32. Klebe G., Abraham U. (1999) Comparative molecular similarity index analysis (CoMSIA) to study hydrogen-bonding properties and to score combinatorial libraries. J Comput Aided Mol Des;13:1-10.
33. Suree N., Yi S.W., Thieu W., Marohn M., Damoiseaux R., Chan A., Jung M.E., Clubb R.T. (2009) Discovery and structure-activity relationship analysis of Staphylococcus aureus sortase A inhibitors. Bioorg Med Chem;17:7174-7185.
34. Clark M., Cramer R.D.I., Van Opdenbosh N. (1989) The tripos force field. J Comput Chem;10:1012.
35. Jakalian A., Jack D.B., Bayly C.I. (2002) Fast, efficient generation of high quality atomic charges. AM1 BCC model: II. Parameterization and validation. J Comput Chem;23:1623-1641.
36. Oshiro C.M., Kuntz I.D., Dixon J.S. (1995) Flexible ligand docking using a genetic algorithm. J Comput Aided Mol Des;9:113-130.
37. Jones G., Willett P., Glen R.C. (1995) A genetic algorithm for flexible molecular overlay and pharmacophore elucidation. J Comput Aided Mol Des;9:532-549.
38. Richard C.D. III, Patterson D.E., Bunce J.D. (1989) Recent advances in comparative molecular field analysis (CoMFA). Prog Clin Biol Res;291:161-165.
39. Bush B.L., Nachbar R.B. (1993) Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA. J Comput Aided Mol Des;7:587-619.
40. Murumkar P.R., Zambre V.P., Yadav M.R. (2010) Development of predictive pharmacophore model for in silico screening, and 3D QSAR CoMFA and CoMSIA studies for lead optimization, for designing of potent tumor necrosis factor alpha converting enzyme inhibitors. J Comput Aided Mol Des;24:143-156.
41. Jiang Q., Liao H., Yang Q., Zan W., Zang Z. (2010) Pharmacophore-based 3D-QSAR as a predictive method for the QSAR analysis on a series of potent and selective inhibitors for three kinases of RTK family. Mol Simulat;36:693-707.
42. Neaz M.M., Pasha F.A., Muddassar M., Lee S.H., Sim T., Hah J.M., Cho S.J. (2009) Pharmacophore based 3D-QSAR study of VEGFR-2 inhibitors. Med Chem Res;18:127-142.
43. Cianchetta G., Singleton R.W., Zhang M., Wildgoose M., Giesing D., Fravolini A., Cruciani G., Vaz R.J. (2005) A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR. J Med Chem;48:2927-2935.
44. Wermuth C.G., Ganellin C.R., Lindberg P., Mitscher L.A. (1998) Glossary of terms used in medicinal chemistry. Pure Appl Chem;70:1129-1143.
45. Mason J.S., Good A.C., Martin E.J. (2001) 3-D pharmacophores in drug discovery. Curr Pharm Des;7:567-597.
46. Marshall G.R., Kubinyi H. (1993) 3D QSAR in Drug Design: Recent Advances. Leiden: Springer Netherlands.
47. Shepphird J.K., Clark R.D. (2006) A marriage made in torsional space: using GALAHAD models to drive pharmacophore multiplet searches. J Comput Aided Mol Des;20:763-771.